ODAC Flattens Taltorvic, Cites Risk/Benefit Profile in Sarcoma
The FDA's oncologic drugs advisory committee (ODAC) voted 13 to 1 against the approval of Taltorvic (ridaforolimus) by Ariad Pharmaceuticals Inc., partnered with Merck & Co. Inc., for soft-tissue and bone sarcoma.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST